title: Risk Stratification of Pediatric Patients With Neuroblastoma Using Volumetric Parameters of 18F-FDG and 18F-DOPA PET/CT.
abstract: OBJECTIVE
  This study determined the prognostic value of volumetric parameters derived from pretreatment F-FDG and F-DOPA PET/CT of neuroblastoma and their correlation with clinical and histopathologic features.
  
  
  METHODS
  A total of 25 children with neuroblastoma underwent pretreatment F-FDG and F-DOPA PET/CT within 4 weeks. The SUVmax of primary tumors on F-FDG and F-DOPA PET were recorded as SUVFDG and SUVDOPA, respectively. For volumetric parameters of primary tumors, 40% of SUVmax was used to generate volume of interest. If the 40% of SUVmax was below 2.5, an SUV threshold of 2.5 was used instead. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), dopaminergic tumor volume (DTV), and total lesion F-DOPA activity (TLDA) were recorded as F-FDG and F-DOPA volumetric parameters. All indices were compared between groups distinguished by survival status and clinical features, including bone marrow involvement, lymph node metastasis, amplification of the MYCN oncogene, invasive features on anatomic images, and risk categories. The Kaplan-Meier method and log-rank test were used to compare the survival curves between groups.
  
  
  RESULTS
  The median follow-up period was 28.2 months. Nonsurvivors (20%) tended to have lower SUVDOPA, DTV, and TLDA (P ≤ 0.05), and higher SUVFDG, MTV, and TLG (all P < 0.05). Lower F-DOPA uptake is associated with bone marrow and lymph node metastases (all P < 0.05). Higher F-FDG uptake is associated with MYCN amplification (all P < 0.05) and anatomic invasive features of tumors such as vascular encasement or adjacent organ invasion (TLG, P = 0.05). Only volumetric indices (DTV, TLDA, MTV, and TLG) significantly differed among risk groups (all P < 0.05).
  
  
  CONCLUSIONS
  Pretherapeutic F-DOPA and F-FDG PET provided complementary information, and both can be served for risk stratification. Volumetric indices of F-DOPA and F-FDG PET correlate more highly with risk grouping.
authors.affiliation: From the Departments of *Nuclear Medicine, and †Pediatrics, National Taiwan University Hospital, Taipei; ‡Department of Pediatrics, Taipei Medical University Hospita, Taipei; §PhD Program in Translational Medicine, National Taiwan University and Academia Sinica, Taipei; ∥Department of Nuclear Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin; ¶Department of Surgery, National Taiwan University Hospital, Taipei; and **Molecular Imaging Center, National Taiwan University, Taipei, Taiwan.
authors.forename: Chia-Ju
authors.initials: CJ
authors.lastname: Liu
authors.forename: Meng-Yao
authors.initials: MY
authors.lastname: Lu
authors.forename: Yen-Lin
authors.initials: YL
authors.lastname: Liu
authors.forename: Chi-Lun
authors.initials: CL
authors.lastname: Ko
authors.forename: Kuan-Yin
authors.initials: KY
authors.lastname: Ko
authors.forename: Kai-Yuan
authors.initials: KY
authors.lastname: Tzen
authors.forename: Hsiu-Hao
authors.initials: HH
authors.lastname: Chang
authors.forename: Yung-Li
authors.initials: YL
authors.lastname: Yang
authors.forename: Shiann-Tarng
authors.initials: ST
authors.lastname: Jou
authors.forename: Wen-Ming
authors.initials: WM
authors.lastname: Hsu
authors.forename: Ruoh-Fang
authors.initials: RF
authors.lastname: Yen
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D054893:Cone-Beam Computed Tomography; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007223:Infant; D008207:Lymphatic Metastasis; D008297:Male; D009447:Neuroblastoma / Q000145:classification / Q000000981:diagnostic imaging* / Q000473:pathology; D000072078:Positron Emission Tomography Computed Tomography; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C043437:fluorodopa F 18; D004295:Dihydroxyphenylalanine